202 related articles for article (PubMed ID: 23522028)
1. Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility.
Jansen A; Szekat C; Schröder W; Wolz C; Goerke C; Lee JC; Türck M; Bierbaum G
BMC Microbiol; 2013 Mar; 13():65. PubMed ID: 23522028
[TBL] [Abstract][Full Text] [Related]
2. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.
Reipert A; Ehlert K; Kast T; Bierbaum G
Antimicrob Agents Chemother; 2003 Feb; 47(2):568-76. PubMed ID: 12543661
[TBL] [Abstract][Full Text] [Related]
3. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus.
Jansen A; Türck M; Szekat C; Nagel M; Clever I; Bierbaum G
Int J Med Microbiol; 2007 Jul; 297(4):205-15. PubMed ID: 17418637
[TBL] [Abstract][Full Text] [Related]
4. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
[TBL] [Abstract][Full Text] [Related]
5. Role of the
G C B; Sahukhal GS; Elasri MO
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31307991
[No Abstract] [Full Text] [Related]
6. The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus.
Hort M; Bertsche U; Nozinovic S; Dietrich A; Schrötter AS; Mildenberger L; Axtmann K; Berscheid A; Bierbaum G
Microbiol Spectr; 2021 Oct; 9(2):e0052821. PubMed ID: 34668723
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
Matsuo M; Cui L; Kim J; Hiramatsu K
Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial Activity of Galangin and Its Effects on Murein Hydrolases of Vancomycin-Intermediate Staphylococcus aureus (VISA) Strain Mu50.
Ouyang J; Sun F; Feng W; Xie Y; Ren L; Chen Y
Chemotherapy; 2018; 63(1):20-28. PubMed ID: 29145175
[TBL] [Abstract][Full Text] [Related]
9. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
Shoji M; Cui L; Iizuka R; Komoto A; Neoh HM; Watanabe Y; Hishinuma T; Hiramatsu K
Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
[TBL] [Abstract][Full Text] [Related]
10. VraR Binding to the Promoter Region of
Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
[TBL] [Abstract][Full Text] [Related]
11. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
Matsuo M; Hishinuma T; Katayama Y; Cui L; Kapi M; Hiramatsu K
Antimicrob Agents Chemother; 2011 Sep; 55(9):4188-95. PubMed ID: 21746940
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation.
Park C; Shin NY; Byun JH; Shin HH; Kwon EY; Choi SM; Kim SH; Kwon JC; Park SH; Choi JH; Yoo JH; Yoo JI; Chung GT; Lee DG
J Med Microbiol; 2012 Mar; 61(Pt 3):345-352. PubMed ID: 22016559
[TBL] [Abstract][Full Text] [Related]
13. Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain.
Di Gregorio S; Fernandez S; Cuirolo A; Verlaine O; Amoroso A; Mengin-Lecreulx D; Famiglietti A; Joris B; Mollerach M
Microb Drug Resist; 2017 Jan; 23(1):44-50. PubMed ID: 27991847
[TBL] [Abstract][Full Text] [Related]
14. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
[TBL] [Abstract][Full Text] [Related]
15. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea.
Kim MN; Hwang SH; Pyo YJ; Mun HM; Pai CH
J Clin Microbiol; 2002 Apr; 40(4):1376-80. PubMed ID: 11923359
[TBL] [Abstract][Full Text] [Related]
16. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
[TBL] [Abstract][Full Text] [Related]
17. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and genotypic changes of Staphylococcus aureus in the presence of the inappropriate concentration of chlorhexidine gluconate.
Baseri N; Najar-Peerayeh S; Bakhshi B; Campanile F
BMC Microbiol; 2022 Apr; 22(1):100. PubMed ID: 35418037
[TBL] [Abstract][Full Text] [Related]
19. Activated ADI pathway: the initiator of intermediate vancomycin resistance in Staphylococcus aureus.
Tan XE; Neoh HM; Looi ML; Chin SF; Cui L; Hiramatsu K; Hussin S; Jamal R
Can J Microbiol; 2017 Mar; 63(3):260-264. PubMed ID: 28059579
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
Kelley PG; Gao W; Ward PB; Howden BP
J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
